Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Jul 21, 2022

(R) Extraordinary general meeting in Cantargia AB (publ)

Jul 21, 2022

(R) Cantargia receives USPTO Notice of Allowance for composition of matter patent on antibody CAN10

Jul 18, 2022

(R) Cantargia announces the terms of its fully covered rights issue

Jul 8, 2022

(R) Cantargia appoints Dr. Dominique Tersago as Chief Medical Officer

Jul 4, 2022

Cantargia to hold webcast briefing on recently announced rights issue

Jun 21, 2022

(R) Notice of extraordinary general meeting in Cantargia AB (publ)

Jun 21, 2022

(R) Cantargia resolves on a fully covered rights issue of approximately SEK 250 million

Jun 9, 2022

Cantargia to host R&D Day on nadunolimab combinational synergy in pancreatic cancer and non-small cell lung cancer

May 26, 2022

(R) Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC

May 26, 2022

(R) Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic cancer

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye